Company intelligence / Profile preview

Nyxoah

Mont-Saint-Guilbert, Belgiumnyxoah.com ↗

Ownership: Public · NYXH
Employees: ~184
Development stage: Other

Overview

The Genio system has demonstrated safety and efficacy for moderate to severe OSA in pivotal clinical trials such as DREAM IDE. It holds CE Mark approval under the new European MDR and has completed all PMA modules for FDA review. US commercialization planned for early 2025 pending FDA approval. European commercial sales ongoing with positive real-world outcomes.

Therapeutic areas: Pulmonology
Modalities: DeviceNeuromodulation therapy (specifically hypoglossal nerve stimulation)
Industry: Therapeutic Medical Devices

Financials

Market cap: $156.1M
Total revenue: $7.7M
Enterprise value: $110.9M

Beyond the preview

Go deeper on Nyxoah.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nyxoah.

Explore the full profile